KR20230065231A - 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료 - Google Patents

에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료 Download PDF

Info

Publication number
KR20230065231A
KR20230065231A KR1020237001004A KR20237001004A KR20230065231A KR 20230065231 A KR20230065231 A KR 20230065231A KR 1020237001004 A KR1020237001004 A KR 1020237001004A KR 20237001004 A KR20237001004 A KR 20237001004A KR 20230065231 A KR20230065231 A KR 20230065231A
Authority
KR
South Korea
Prior art keywords
cancer
epha2
patient
tumor tissue
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001004A
Other languages
English (en)
Korean (ko)
Inventor
개빈 베넷
스티븐 블레이크모어
칼리 캠프벨
마이클 릭비
Original Assignee
바이사이클티엑스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이사이클티엑스 리미티드 filed Critical 바이사이클티엑스 리미티드
Publication of KR20230065231A publication Critical patent/KR20230065231A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • G01N33/57484—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020237001004A 2020-06-12 2021-06-11 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료 Pending KR20230065231A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038279P 2020-06-12 2020-06-12
US63/038,279 2020-06-12
PCT/GB2021/051451 WO2021250418A1 (en) 2020-06-12 2021-06-11 Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)

Publications (1)

Publication Number Publication Date
KR20230065231A true KR20230065231A (ko) 2023-05-11

Family

ID=76641715

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001004A Pending KR20230065231A (ko) 2020-06-12 2021-06-11 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료

Country Status (10)

Country Link
US (1) US20230233698A1 (https=)
EP (1) EP4165414A1 (https=)
JP (1) JP2023529214A (https=)
KR (1) KR20230065231A (https=)
CN (1) CN115698720A (https=)
AU (1) AU2021289095A1 (https=)
CA (1) CA3180095A1 (https=)
IL (1) IL298868A (https=)
MX (1) MX2022015419A (https=)
WO (1) WO2021250418A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155830B (zh) * 2005-02-04 2014-06-18 雷文生物技术公司 结合epha2的抗体及其使用方法
US20100254996A1 (en) * 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
US20110281279A1 (en) * 2007-12-21 2011-11-17 Siemens Healthcare Diagnostics Inc. CIRCULATING Epha2 RECEPTOR
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
KR20140067052A (ko) * 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
WO2016171242A1 (ja) * 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
JP2019512477A (ja) * 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CN109700812A (zh) * 2019-01-18 2019-05-03 厦门大学 一种治疗表达parp10的肝细胞癌的药物组合物及其应用
SG11202110828UA (en) * 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
MX2022006001A (es) * 2019-11-27 2022-10-27 Bicycletx Ltd Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos.

Also Published As

Publication number Publication date
AU2021289095A1 (en) 2023-01-05
CA3180095A1 (en) 2021-12-16
MX2022015419A (es) 2023-03-17
JP2023529214A (ja) 2023-07-07
CN115698720A (zh) 2023-02-03
US20230233698A1 (en) 2023-07-27
EP4165414A1 (en) 2023-04-19
IL298868A (en) 2023-02-01
WO2021250418A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
KR20230065231A (ko) 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료
EP3229844B1 (en) Antibody drug conjugates with cell permeable bcl-xl inhibitors
JP2020128378A (ja) Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
CA3027178A1 (en) Anti-egfr antibody drug conjugates
CN119173278A (zh) 抗体偶联药物及其用途
CN114269389A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
CN115715201A (zh) 葡萄糖雷公藤甲素缀合物及其用途
US20230039711A1 (en) Ahr inhibitors and uses thereof
JP2024521418A (ja) 放射性免疫複合体とチェックポイント阻害剤併用療法
US12612431B2 (en) Cyclic compounds for treating cancer
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
EP4631956A1 (en) Linker, linker-containing antibody drug conjugate, and preparation method therefor and use thereof
CN121969398A (zh) 抗体偶联药物及其用途
US20200270224A1 (en) Heterocyclic Ligands of PAR1 and Methods of Use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902